|
Collaborative, Licensing and Other Arrangements (Details) (National Institute of Allergy and Infectious Diseases "NIAID" [Member], Arrangement with Governmental Agency 3 [Member], USD $)
In Millions, unless otherwise specified |
3 Months Ended | |
|---|---|---|
|
Sep. 30, 2014
|
Sep. 30, 2008
|
|
|
National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 3 [Member]
|
||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Total contract amount awarded | $ 65 | |
| Decrease in deferred revenue | (1.8) | |
| Recognition of deferred revenue | $ 1.9 |
| X | ||||||||||
|
- Definition
Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net addition or reduction in the carrying amount of deferred revenue during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|